About Stratec Biomedical AG (ETR:SBS)
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes. The company also develops laboratory data management software, including Aurora Touch, Aurora Vigilant, Aurora AccLaIM, Aurora Stats, Aurora Morpheus, and Aurora Liberty SRImport for laboratories, diagnostic companies, and instrument manufacturers. In addition, it offers a range of optimized solutions for DNA and RNA preparation from various samples for applications in clinical diagnostics and life science research, including genomic DNA, viral RNA and DNA, bacterial DNA, total RNA, DNA fragments and pDNA, universal nucleic acid purification product line, automated sample preparation, enzymes, and reagents; and invests in other companies. Further, the company develops workflow software for networking several analyzer systems. STRATEC Biomedical AG has operations in Germany and other European Union countries, and internationally. The company was formerly known as STRATEC Biomedical Systems AG and changed its name to STRATEC Biomedical AG in April 2011. STRATEC Biomedical AG was founded in 1979 and is headquartered in Birkenfeld, Germany.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: ETR:SBS
- CUSIP: N/A
- Web: www.stratec.com/
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: 5.46%
- Return on Equity: 7.76%
- Return on Assets: 4.39%
Frequently Asked Questions for Stratec Biomedical AG (ETR:SBS)
What is Stratec Biomedical AG's stock symbol?
Stratec Biomedical AG trades on the ETR under the ticker symbol "SBS."
Where is Stratec Biomedical AG's stock going? Where will Stratec Biomedical AG's stock price be in 2017?
5 brokerages have issued 1-year price objectives for Stratec Biomedical AG's stock. Their predictions range from €55.00 to €66.00. On average, they expect Stratec Biomedical AG's stock price to reach €60.00 in the next twelve months. View Analyst Ratings for Stratec Biomedical AG.
Who are some of Stratec Biomedical AG's key competitors?
Some companies that are related to Stratec Biomedical AG include Aareal Bank AG (ARL), Adler Real Estate AG (ADL), ADO Properties SA (ADJ), ADVA Optical Networking SE (ADV), Aixtron Se (AIXA), Aurubis AG (NDA), Basf Se (BAS), Bayerische Motoren Werke AG (BMW), BayWa AG (BYW6), Bechtle AG (BC8), Beiersdorf AG (BEI), Bertrandt AG (BDT), bet-at-home.com AG (ACX), Bilfinger SE (GBF), Biotest AG (BIO), Cancom SE (COK), Capital Stage AG (CAP) and Carl Zeiss Meditec AG (AFX).
Who are Stratec Biomedical AG's key executives?
MarketBeat Community Rating for Stratec Biomedical AG (ETR SBS)MarketBeat's community ratings are surveys of what our community members think about Stratec Biomedical AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Stratec Biomedical AG's management team includes the folowing people:
- Fred K. Brueckner, Chairman of the Supervisory Board
- Marcus Wolfinger, Chairman of the Management Board, Chief Executive Officer
- Robert Siegle, Director of Finance and Human Resources, Member of the Board of Management
- Andreas Kuenzel, Director of Investor Relations
- Claus Vielsack, Member of the Management Board, Director of Product Development
- Roland Baule, Member of the Supervisory Board
- Stefanie Remmele, Member of the Supervisory Board
Consensus Ratings for Stratec Biomedical AG (ETR:SBS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 2 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.40)|
|Consensus Price Target: ||€60.00|Consensus Price Target History for Stratec Biomedical AG (ETR:SBS)
Analysts' Ratings History for Stratec Biomedical AG (ETR:SBS)
(Data available from 10/23/2015 forward)
|7/27/2017||Deutsche Bank AG||Set Price Target||Neutral||€55.00|
|7/26/2017||Kepler Capital Markets||Set Price Target||Buy||€66.00|
|7/25/2017||Warburg Research||Set Price Target||Buy||€62.00|
|7/25/2017||Berenberg Bank||Set Price Target||Neutral||€59.00|
|7/24/2017||Oddo Securities||Set Price Target||Neutral||€58.00|
Earnings History for Stratec Biomedical AG (ETR:SBS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Stratec Biomedical AG (ETR:SBS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Stratec Biomedical AG (ETR:SBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Stratec Biomedical AG (ETR:SBS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Stratec Biomedical AG (ETR:SBS)
Latest Headlines for Stratec Biomedical AG (ETR:SBS)
Loading headlines, please wait.